|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2007 / October 2007 / October 24, 2007 Obesity drug Contrave acts on specific brain pathways to reduce hunger pangs |
Structure of key breast cancer target enzyme unraveled
A researcher at Hauptman-Woodward Medical Research Institute has moved a step closer to a cure, and possibly the prevention, of the most common type of breast cancer. ANI
Smoking claimed 673,000 Chinese lives in 2005
A multinational research team, led by scientists at Tulane University School of Public Health and Tropical Medicine, has lent more force to the suggestion that smoking is a significant risk factor for mortality and disease. ANI
Genetic mutations can predict childhood leukaemia relapse
A collaborative study by American researchers has revealed that changes in a gene called IKAROS can help predict a high likelihood of relapse in children with acute lymphoblastic leukaemia (ALL). ANI
Biopharmaceutical company Orexigen Therapeutics, Inc. has unveiled the results of a pre-clinical research into the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.
Washington, October 24 : Biopharmaceutical company Orexigen Therapeutics, Inc. has unveiled the results of a pre-clinical research into the mechanism of action of Contrave, one of its two late-stage obesity drug candidates.
The company revealed that the combination of bupropion and naltrexone, the components of Contrave, resulted in a 94 per cent reduction of food intake in obese mice, greater than either drug alone.
The study also revealed that the drugs acted in a part of the brain where food reward pathways are located.
The drug combo directly increased firing of neurons associated with reduction in food intake and satiety.
"We originally theorized that the combination of bupropion and naltrexone, the components of Contrave, would stimulate proopiomelanocortin (POMC) neuronal firing which would lead to sustained weight loss. These new findings indicate that Contrave may also modulate food cravings through its effect on reward pathways," said Orexigen founder and Chief Scientific Officer, Dr. Michael Cowley.
"We believe this aspect of Contrave's mechanism of action may have the potential to differentiate it from other pharmaceutical therapies available or in development for the treatment of obesity," Dr. Cowley added.
In one study, the effects of bupropion, naltrexone and the combination of both drugs were examined in both lean and obese mice.
It was found that treatments with bupropion, naltrexone or the combination resulted in a 34 per cent, 67 per cent, and 77 per cent reduction of food intake in lean mice. By contrast, the same treatments resulted in a 27 per cent, 49 per cent, and 94 per cent reduction of food intake in obese mice.
The interaction between bupropion and naltrexone appeared more potent in obese mice than in lean mice.
In a separate study, the effects of the same three therapies were examined by administering them selectively to the ventral tegmental area (VTA), a part of the brain that determines whether an environmental stimulus is rewarding or aversive.
The drug combo in the VTA caused a statistically significant, synergistic reduction of food intake suggesting a possible connection to the behavioural aspects of obesity.
The data were presented at The Obesity Society's Annual Scientific Meeting (NAASO) in New Orleans.
ANI
